Iron regulatory hormone hepcidin decreases in chronic heart failure patients with anemia

Circulation Journal

Volumn 74, Issue 2, 2010, Pages 301-306

  Matsumoto, Mika ^a   Tsujino, Takeshi ^a   Lee Kawabata, Masaaki ^a   Naito, Yoshiro ^a   Akahori, Hirokuni ^a   Sakoda, Tsuyoshi ^a   Ohyanagi, Mitsumasa ^a   Tomosugi, Naohisa ^b   Masuyama, Tohru ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anemia of inflammation; Chronic heart failure; Hepcidin 25; Interleukin 6

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEPCIDIN; INTERLEUKIN 6;

AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEART FAILURE; HUMAN; INFLAMMATION; IRON STORAGE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANEMIA; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DOWN-REGULATION; ERYTHROPOIETIN; FEMALE; FERRITINS; HEART FAILURE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; LINEAR MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 75749095641     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0663     Document Type: Article

References (35)

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
2. Ganz T, Nemeth E. Iron imports. IV: Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2006; 290: 199-203.
3. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
4. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819.
5. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-1044.
6. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
7. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12065 patients with new-onset heart failure. Circulation 2003; 107: 223-225.
8. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 2003; 41: 1933-1939.
9. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002; 39: 1780-1786.
10. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000; 35: 1737-1744.
11. Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, Yokota T, Takeshita A, Yokoshiki H, et al; JCARE-CARD Investigators. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan: A Report From the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-1908.
12. Kawashiro N, Kasanuki H, Ogawa H, Matsuda N, Hagiwara N; Heart Institute of Japan-Department of Cardiology (HIJC) Investigators. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: Results of the HIJC-HF registry. Circ J 2008; 72: 2015-2020.
13. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, et al. Hemodilution is common in patients with advanced heart failure. Circulation 2003; 107: 226-229.
14. Adlbrecht C, Kommata S, Hülsmann M, Szekeres T, Bieglmayer C, Strunk G, et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008; 29: 2343-2350.
15. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006; 48: 2485-2489.
16. van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 2008; 4: 47-57.
17. Manjunath G, Sarnak MJ, Levey AS. Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 2001; 10: 785-792.
18. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
19. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007; 110: 1048-1054.
20. Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 2007; 21: 4033-4038.
21. Kanda J, Mizumoto C, Kawabata H, Tsuchida H, Tomosugi N, Matsuo K, et al. Serum hepcidin level and erythropoietic activity after hematopoietic stem cell transplantation. Haematologica 2008; 93: 1550-1554.
22. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. Blood 2002; 100: 3776-3781.
23. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 2006; 55: 667-674.
24. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13: 1096-1101.
25. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478-481.
26. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487.
27. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 2007; 117: 1926-1932.
28. Mauran P, Pham I, Sediame S, Jolly D, Chabrier PE, Carayon A, et al. Increased erythropoietin synthesis in patients with COLD or left heart failure is related to alterations in renal haemodynamics. Eur J Clin Invest 2001; 31: 103-109.
29. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-1276.
30. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-1866.
31. Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387.
32. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 2007; 92: 857-858.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
34. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-3067.
35. Bayele HK, Srai SK. Genetic variation in hepcidin expression and its implications for phenotypic differences in iron metabolism. Haematologica 2009; 94: 1185-1188.